DFX Intelligence

Data Factory

Private equityFirmventure with pe activity · probableunsized

Avoro Capital Advisors LLC

Private Equity

New York, NY

Avoro Capital Advisors is a global firm focused on funding & investments in biotechnology, life sciences, and specialty therapeutics. Contact us today!

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:2835cad0-9f4b-4c70-9bf3-17c4f91f3678

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 8:33 PM UTC and rebuilt at most every 15 minutes.

Relationships: 153
Dated events: 15
On other graphs: 2
Observed: Sep 13, 2026 to Sep 17, 2026
29 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

Avoro Capital Advisors LLC

Venture manager · shared crd

RIA / Wealth Managementidentity

AVORO CAPITAL ADVISORS LLC

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 2
PE funds: 0
Vintages: 2016 to 2016
Regulatory AUM: $8.7B
Investments: 105
Active investments: 54
Size band: UNSIZEDderivedno Private Equity Fund GAV on a filing from 2021 or later
Stated sectors: life_sciences
Latest ADV filing: Jun 4, 2024
Employees (ADV): 15
Website: avorocapital.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV	LPs
Venbio Global Strategic Fund II, L.P.	2016	Unknown	Venture Capital Fund	n/a	$315M	0
Venbio Global Strategic Fund, L.P.	n/a	Mature	Venture Capital Fund	n/a	$179M	0

Investments

Company	State	Role	Control	Invested	Exited	Status
Aeriepharma	n/a	unknown	unknown	n/a	n/a	active
Ottimo Pharma	n/a	unknown	unknown	n/a	n/a	active
Adverum Biotechnologoes	n/a	unknown	unknown	n/a	n/a	active
Viveve Medical (VIVE)	n/a	unknown	unknown	n/a	n/a	active
merus.nl	n/a	unknown	unknown	n/a	n/a	active
Assembly Biosciences (ASMB)	n/a	unknown	unknown	n/a	n/a	active
Avidity	n/a	unknown	unknown	n/a	n/a	active
Horizon Therapeutics	n/a	unknown	unknown	n/a	n/a	active
Acerta Pharma	n/a	unknown	unknown	n/a	n/a	active
Kura Oncology, Inc.	CA	unknown	unknown	n/a	n/a	active
Krystal Biotech	n/a	unknown	unknown	n/a	n/a	active
Rocket Pharma	n/a	unknown	unknown	n/a	n/a	active
Outlook Therapeutics, Inc.	Nj	unknown	unknown	n/a	n/a	active
Zealand Pharma	n/a	unknown	unknown	n/a	n/a	active
Ascendispharma	n/a	unknown	unknown	n/a	n/a	active
Avadel Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	active
Hemab Therapeutics	n/a	unknown	unknown	n/a	n/a	active
Apellis	n/a	unknown	unknown	n/a	n/a	active
Mirati Therapeutics	n/a	unknown	unknown	n/a	n/a	active
Tricida (TCDA)	n/a	unknown	unknown	n/a	n/a	active
ViceBio	n/a	unknown	unknown	n/a	n/a	active
Amarincorp	n/a	unknown	unknown	n/a	n/a	active
Olema Pharmaceuticals, Inc.	CA	unknown	unknown	n/a	n/a	active
Fennec Pharmaceuticals (FENC)	n/a	unknown	unknown	n/a	n/a	active
Vanqua Bio, Inc.	IL	unknown	unknown	n/a	n/a	active
Nantkwest	n/a	unknown	unknown	n/a	n/a	active
Adverum	n/a	unknown	unknown	n/a	n/a	unknown
Aerie	n/a	unknown	unknown	n/a	n/a	unknown
Allogene	n/a	unknown	unknown	n/a	n/a	unknown
Amarin	n/a	unknown	unknown	n/a	n/a	unknown

Relationships

showing 80 of 153

Invested in (61)

→ Xenon PharmaceuticalsCompanyunknown
factDFX's own graph
→ IovanceCompanyunknown
factDFX's own graph
→ Allogene TherapeuticsCompanyunknown
factDFX's own graph
→ Karyopharm TherapeuticsCompanyunknown
factDFX's own graph
→ Zealand PharmaCompanyunknown
factDFX's own graph, The subject's own site
→ Vividion TherapeuticsCompanyunknown
factDFX's own graph
→ Fennec Pharmaceuticals (FENC)Companyunknown
factDFX's own graph
→ Corvus Pharmaceuticals (CRVS)Companyunknown
factDFX's own graph
→ Vanqua Bio, Inc.Companyunknown
factDFX's own graph
→ Kura Oncology, Inc.Companyunknown
factDFX's own graph
→ Trillium TherapeuticsCompanyunknown
factDFX's own graph
→ AscendispharmaCompanyunknown
factDFX's own graph
→ ApellisCompanyunknown
factDFX's own graph
→ Viking TherapeuticsCompanyunknown
factDFX's own graph
→ Mirati TherapeuticsCompanyunknown
factDFX's own graph
→ PMV PharmaceuticalsCompanyunknown
factDFX's own graph
→ Viveve Medical (VIVE)Companyunknown
factDFX's own graph
→ Krystal BiotechCompanyunknown
factDFX's own graph
→ merus.nlCompanyunknown
factDFX's own graph
→ Global Blood (GBT)Companyunknown
factDFX's own graph
→ MadrigalCompanyunknown
factDFX's own graph
→ Stemline Therapeutics (STML)Companyunknown
factDFX's own graph
→ AdaptimmuneCompanyunknown
factDFX's own graph, The subject's own site
→ Constellation PharmaceuticalsCompanyunknown
factDFX's own graph
→ IvericCompanyunknown
factDFX's own graph
→ AmarincorpCompanyunknown
factDFX's own graph
→ Cymabay TherapeuticsCompanyunknown
factDFX's own graph
→ Sarepta Therapeutics (SRPT)Companyunknown
factDFX's own graph
→ Adverum BiotechnologoesCompanyunknown
factDFX's own graph
→ DiceCompanyunknown
factDFX's own graph
and 31 more

Employs (16)

→ Behzad AghazadehPersonPhD | Managing Partner & Portfolio Manager
factThe subject's own site
→ Neil CammarosanoPersonCPA | Chief Financial Officer
factThe subject's own site
→ Matthew CanverPersonMD/PhD | Director
factThe subject's own site
→ Diane ChienPersonCPA | Hedge Fund Controller
factThe subject's own site
→ Mark ChinPersonInvestment Partner - Avoro Ventures
factThe subject's own site
→ Uya ChuluunbaatarPersonPhD | Investment Partner – Avoro Ventures
factThe subject's own site
→ Scott Andrew EpsteinPersonPartner, Chief Operating Officer & Chief Compliance Officer
factThe subject's own site
→ Lauren GodlaskyPersonHead of Investor Relations & Marketing
factThe subject's own site
→ Corie HansenPersonOffice Manager / Executive Assistant
factThe subject's own site
→ Susana Wilson HawkenPersonPhD | Associate
factThe subject's own site
→ Max IsbergPersonSenior Analyst
factThe subject's own site
→ Jenna McElhinneyPersonManager | Investor Relations & Marketing
factThe subject's own site
→ Bryan PhillipsPersonJD | Deputy Chief Compliance Officer
factThe subject's own site
→ Molly ReichhardPersonReceptionist / Executive Assistant
factThe subject's own site
→ Billy SmithPersonAssociate
factThe subject's own site
→ David XiangPersonMD MPH | Associate
factThe subject's own site

Dated events

2 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Jun 16, 2026
Firm news
Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion
The subject's own siteobserved 2 days ago
Occurred
May 1, 2024
Person joined
Neil Cammarosano joined Schedule A of Avoro Capital Advisors LLC as Chief Financial Officer
Form ADVobserved 6 days ago
Occurred
May 1, 2019
Person joined
Garheng Albert Kong joined Schedule A of Avoro Capital Advisors LLC as Member
Form ADVobserved 6 days ago
Occurred
Sep 28, 2017
Person left
Corey S. Goodman (Manager) no longer on Schedule A of Avoro Capital Advisors LLC
Form ADVobserved 6 days ago
Occurred
Sep 28, 2017
Person left
Robert Adelman (Manager) no longer on Schedule A of Avoro Capital Advisors LLC
Form ADVobserved 6 days ago
Occurred
Mar 29, 2016
Person left
Paul Alan Brooke (Manager) no longer on Schedule A of Avoro Capital Advisors LLC
Form ADVobserved 6 days ago
Occurred
Jan 13, 2015
Person left
Konrad Hans Vonemster (Manager) no longer on Schedule A of Avoro Capital Advisors LLC
Form ADVobserved 6 days ago
Occurred
Jun 1, 2014
Person joined
Scott Andrew Epstein joined Schedule A of Avoro Capital Advisors LLC as Chief Financial Officer And Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Apr 1, 2013
Person joined
Robert Adelman joined Schedule A of Avoro Capital Advisors LLC as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Jan 1, 2013
Person joined
Paul Alan Brooke joined Schedule A of Avoro Capital Advisors LLC as Manager
Form ADVobserved 6 days ago
Occurred
Jan 1, 2013
Person joined
Corey S. Goodman joined Schedule A of Avoro Capital Advisors LLC as Manager
Form ADVobserved 6 days ago
Occurred
Feb 22, 2012
Adviser first adv filing
Avoro Capital Advisors LLC first filed Form ADV in the extract (IA)
Form ADVobserved 6 days ago
Occurred
Jul 1, 2011
Person joined
Behzad Aghazadeh joined Schedule A of Avoro Capital Advisors LLC as Portfolio Manager
Form ADVobserved 6 days ago

Show 2 bookkeeping events

Occurred
Mar 29, 2016
Venbio Global Strategic Fund II, L.P. first reported on Form ADV by Avoro Capital Advisors LLC (Private Equity Fund), GAV $290,909,091
Occurred
Feb 22, 2012
Venbio Global Strategic Fund, L.P. first reported on Form ADV by Avoro Capital Advisors LLC (Private Equity Fund), GAV $179,000,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV), 1 work email (firm website) · as of 2026-09-17

Also named here, with no published line of their own (reach them through the firm): Behzad Aghazadeh (PhD | Managing Partner & Portfolio Manager), Neil Cammarosano (CPA | Chief Financial Officer), Matthew Canver (MD/PhD | Director), Diane Chien (CPA | Hedge Fund Controller), Mark Chin (Investment Partner - Avoro Ventures), Uya Chuluunbaatar (PhD | Investment Partner – Avoro Ventures), Scott Andrew Epstein (Partner, Chief Operating Officer & Chief Compliance Officer), Lauren Godlasky (Head of Investor Relations & Marketing), Corie Hansen (Office Manager / Executive Assistant), Susana Wilson Hawken (PhD | Associate), Max Isberg (Senior Analyst), Jenna McElhinney (Manager | Investor Relations & Marketing).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:2835cad0-9f4b-4c70-9bf3-17c4f91f3678
First observed: Sep 13, 2026
Last observed: Sep 17, 2026 2 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Avoro Capital Advisors LLC

Private Equity

New York, NY

Avoro Capital Advisors is a global firm focused on funding & investments in biotechnology, life sciences, and specialty therapeutics. Contact us today!

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:2835cad0-9f4b-4c70-9bf3-17c4f91f3678

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 8:33 PM UTC and rebuilt at most every 15 minutes.